Real-world treatment switching and healthcare costs of onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibodies in Medicare patients with chronic migraine: a retrospective claims analysis

Patients with CM on a CGRP mAb were significantly more likely to switch to a different branded migraine preventive treatment within 12 months of treatment initiation compared to those on onabotA. Total costs were comparable between treatments.